Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2025

7/16/25 6:25:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $JNJ alert in real time by email

Johnson & Johnson (NYSE:JNJ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2025 of $1.30 per share on the company's common stock. The dividend is payable on September 9, 2025 to shareholders of record at the close of business on August 26, 2025. The ex-dividend date is August 26, 2025.

About Johnson & Johnson

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at https://www.jnj.com/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250715350667/en/

Media:

[email protected]

Investors:

[email protected]

Get the next $JNJ alert in real time by email

Recent Analyst Ratings for

$JNJ

Date	Price Target	Rating	Analyst
5/13/2025	$153.00	Outperform → Market Perform	Leerink Partners
12/10/2024	$166.00	Neutral	BofA Securities
11/15/2024	$190.00	Outperform	Wolfe Research
7/23/2024	$160.00 → $150.00	Outperform → Neutral	Daiwa Securities
5/30/2024	$160.00	Neutral	Goldman
4/18/2024	$170.00	Hold → Buy	HSBC Securities
12/13/2023	$170.00 → $163.00	Overweight → Equal Weight	Wells Fargo
12/1/2023	$167.00 → $180.00	Neutral → Buy	UBS

More analyst ratings

Recent Analyst Ratings for

$JNJ

Date	Price Target	Rating	Analyst
5/13/2025	$153.00	Outperform → Market Perform	Leerink Partners
12/10/2024	$166.00	Neutral	BofA Securities
11/15/2024	$190.00	Outperform	Wolfe Research
7/23/2024	$160.00 → $150.00	Outperform → Neutral	Daiwa Securities
5/30/2024	$160.00	Neutral	Goldman
4/18/2024	$170.00	Hold → Buy	HSBC Securities
12/13/2023	$170.00 → $163.00	Overweight → Equal Weight	Wells Fargo
12/1/2023	$167.00 → $180.00	Neutral → Buy	UBS

More analyst ratings

Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2025

Crush Q3 2025 with the Best AI Executive Assistant

Recent Analyst Ratings for $JNJ

Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2025

Crush Q3 2025 with the Best AI Executive Assistant

Recent Analyst Ratings for $JNJ

$JNJ SEC Filings

Johnson & Johnson filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 11-K filed by Johnson & Johnson

SEC Form 11-K filed by Johnson & Johnson

$JNJ Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

New insider Pinto Daniel E claimed no ownership of stock in the company (SEC Form 3)

SEC Form 4 filed by Director Hewson Marillyn A

SEC Form 4 filed by Director Woods Eugene A.

$JNJ Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Johnson & Johnson downgraded by Leerink Partners with a new price target

BofA Securities resumed coverage on Johnson & Johnson with a new price target

Wolfe Research initiated coverage on Johnson & Johnson with a new price target

$JNJ Financials

Live finance-specific insights

Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2025

Johnson & Johnson Reports Q2 2025 Results; Raises 2025 Outlook

Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results

$JNJ Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Johnson & Johnson

SEC Form SC 13G/A filed by Johnson & Johnson (Amendment)

SEC Form SC 13G/A filed by Johnson & Johnson (Amendment)

$JNJ Leadership Updates

Live Leadership Updates

Johnson & Johnson Elects Daniel Pinto, President, JPMorganChase to its Board of Directors

Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan

Johnson & Johnson Announces Darren Snellgrove as Vice President, Investor Relations

$JNJ FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

July 21, 2023 - FDA Roundup: July 21, 2023

May 5, 2022 - Coronavirus (COVID-19) Update: FDA Limits Use of Janssen COVID-19 Vaccine to Certain Individuals

August 18, 2021 - Joint Statement from HHS Public Health and Medical Experts on COVID-19 Booster Shots

$JNJ Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Weinberger Mark A bought $147,220 worth of shares (1,000 units at $147.22) (SEC Form 4)

$JNJ Press Releases

Fastest customizable press release news feed in the world

Johnson & Johnson receives U.S. FDA Priority Review for TAR-200 NDA in high-risk non-muscle invasive bladder cancer

Dean Omar Branham Shirley Attorney Named Among Nation's Top Future Legal Leaders

Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2025

Recent Analyst Ratings for
$JNJ

Recent Analyst Ratings for
$JNJ

$JNJ
SEC Filings

$JNJ
Insider Trading

$JNJ
Analyst Ratings

$JNJ
Financials

$JNJ
Large Ownership Changes

$JNJ
Leadership Updates

$JNJ
FDA approvals

$JNJ
Insider Purchases

$JNJ
Press Releases